Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21084094 | 1.00 | HDAC6 (0.50) | HDAC6HDAC8HDAC11HDAC1HDAC3 | |
| SCHEMBL21084135 | 0.93 | HDAC6 (0.55) | HDAC6HDAC8HDAC11HDAC1HDAC3 | |
| SCHEMBL21084087 | 0.93 | HDAC6 (0.55) | HDAC6HDAC8HDAC11HDAC1HDAC3 | |
| SCHEMBL18144782 | 0.93 | HDAC6 (0.49) | HDAC6HDAC8HDAC11HDAC1 | |
| SCHEMBL18165464 | 0.93 | HDAC6 (0.49) | HDAC6HDAC8HDAC11HDAC1 | |
| SCHEMBL18144786 | 0.93 | HDAC6 (0.49) | HDAC6HDAC8HDAC11HDAC1 | |
| SCHEMBL21084154 | 0.89 | ALDH1A1 (0.44) | HDAC6HDAC8HDAC11 | |
| SCHEMBL18148483 | 0.86 | HDAC6 (0.57) | HDAC6HDAC8HDAC11HDAC1 | |
| SCHEMBL18144918 | 0.86 | HDAC6 (0.52) | HDAC6HDAC8HDAC11HDAC1 | |
| SCHEMBL18144838 | 0.86 | HDAC6 (0.52) | HDAC6HDAC8HDAC11HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874649-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-12-29 | — | — | US | claimed |
| US-20200121655-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | Valo Health, LLC | 2020-04-23 | — | — | US | claimed |
| EP-3472131-B1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | FORMA THERAPEUTICS INC (US) | 2020-02-19 | — | — | EP | claimed |
| US-20190201384-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | Valo Health, LLC | 2019-07-04 | — | — | US | claimed |
| US-12213969-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO HEALTH, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20230414585-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | VALO EARLY DISCOVERY, INC. | 2023-12-28 | — | — | US | disclosed |
| US-11730721-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO HEALTH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730721-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO HEALTH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730721-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO HEALTH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210186940-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210186940-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2021-06-24 | — | — | US | disclosed |
| US-10874649-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10874649-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200121655-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | Valo Health, LLC | 2020-04-23 | — | — | US | disclosed |
| US-20200121655-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | Valo Health, LLC | 2020-04-23 | — | — | US | disclosed |
| EP-3472131-B1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | FORMA THERAPEUTICS INC (US) | 2020-02-19 | — | — | EP | disclosed |
| US-10555935-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10555935-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190201384-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | Valo Health, LLC | 2019-07-04 | — | — | US | disclosed |
| US-20190201384-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | Valo Health, LLC | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414585-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | HDAC5, HDAC2, HDAC1 | HDAC6 4/4885HDAC8 7/4885HDAC11 5/4885 |
| US-20210186940-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | HDAC5, HDAC2, HDAC1 | HDAC6 4/4885HDAC8 7/4885HDAC11 5/4885 |
| US-10874649-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | HDAC5, HDAC2, HDAC1 | HDAC6 4/4885HDAC8 7/4885HDAC11 5/4885 |
| US-10555935-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | HDAC5, HDAC2, HDAC1 | HDAC6 4/4885HDAC8 7/4885HDAC11 5/4885 |
| US-20190201384-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | HDAC5, HDAC2, HDAC1 | HDAC6 4/4885HDAC8 7/4885HDAC11 5/4885 |
| US-12213969-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | HDAC5, HDAC2, HDAC1 | HDAC6 4/4885HDAC8 7/4885HDAC11 5/4885 |
| US-20200121655-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | HDAC5, HDAC2, HDAC1 | HDAC6 4/4885HDAC8 7/4885HDAC11 5/4885 |
| US-11730721-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | HDAC5, HDAC2, HDAC1 | HDAC6 4/4885HDAC8 7/4885HDAC11 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.